CSIMarket
 


Sunshine Biopharma Inc   (SBFM)
Other Ticker:  
 

Sunshine Biopharma Inc 's Leverage Ratio

SBFM's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 7.29%, Leverage Ratio fell to 0.26, below the Sunshine Biopharma Inc 's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the third quarter 2023, 140 other companies have achieved lower Leverage Ratio than Sunshine Biopharma Inc in the III Quarter 2023. While Leverage Ratio total ranking has deteriorated compared to the second quarter 2023 from 381 to 436 .

Explain Leverage Ratio?
Who are SBFM Customers?
What are SBFM´s Total Liabilities?


SBFM Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Change -45.61 % -44.83 % 9079.48 % - -
Y / Y Total Liabilities Change 1084.23 % 4962.3 % 279.76 % 107.2 % -82.15 %
Leverage Ratio MRQ 0.26 0.23 0.39 0.35 0.01
SBFM's Total Ranking # 436 # 381 # 876 # 952 # 13
Seq. Equity Change -4.96 % 18.94 % -10.16 % -46.45 % -3.59 %
Seq. Total Liabilities Change 7.29 % -29.91 % -0.71 % 1486.03 % 358.65 %



Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 141
Healthcare Sector # 233
Overall Market # 436


Leverage Ratio Statistics
High Average Low
23.73 3.92 0
(Sep 30 2018)   (Jun 30 2022)




Financial Statements
Sunshine Biopharma Inc 's Equity $ 22 Millions Visit SBFM's Balance sheet
Sunshine Biopharma Inc 's Total Liabilities $ 6 Millions Visit SBFM's Balance sheet
Source of SBFM's Sales Visit SBFM's Sales by Geography


Cumulative Sunshine Biopharma Inc 's Leverage Ratio

SBFM's Leverage Ratio for the trailling 12 Months

SBFM Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity TTM Growth -45.61 % -44.83 % 9079.48 % - -
Y / Y Total Liabilities TTM Growth 1084.23 % 4962.3 % 279.76 % 107.2 % -82.15 %
Leverage Ratio TTM 0.3 0.2 0.13 0.1 0.08
Total Ranking TTM # 623 # 450 # 289 # 222 # 181
Seq. Equity TTM Growth -4.96 % 18.94 % -10.16 % -46.45 % -3.59 %
Seq. Total Liabilities TTM Growth 7.29 % -29.91 % -0.71 % 1486.03 % 358.65 %


On the trailing twelve months basis Due to the net new borrowings of 7.29% during the trailing twelve months finishing in the III Quarter 2023, cumulativeLeverage Ratio improved to 0.3, a new company high.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry SBFM recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has deteriorated during the twelve months ending in the III Quarter 2023, compared to the prior period, from 1 to 3.

Explain Leverage Ratio?
Who are SBFM Customers?
What are SBFM´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 1
Within the Market # 436


trailing twelve months Leverage Ratio Statistics
High Average Low
0.3 0.17 0.08
(Sep 30 2023)   (Sep 30 2022)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Equity
Gain Therapeutics inc  0.71 $ 5.182  Millions$ 7.331  Millions
Vyne Therapeutics Inc   0.67 $ 7.762  Millions$ 11.505  Millions
Guardion Health Sciences Inc   0.67 $ 5.176  Millions$ 7.702  Millions
Organogenesis Holdings Inc   0.67 $ 185.782  Millions$ 276.865  Millions
Vincerx Pharma Inc   0.67 $ 10.535  Millions$ 15.741  Millions
Generation Bio Co   0.64 $ 149.578  Millions$ 231.914  Millions
Salarius Pharmaceuticals inc   0.64 $ 3.868  Millions$ 6.084  Millions
Prophase Labs Inc   0.63 $ 35.282  Millions$ 56.428  Millions
Alkermes Plc   0.62 $ 845.096  Millions$ 1,355.583  Millions
Cue Biopharma Inc   0.62 $ 26.330  Millions$ 42.666  Millions
Harmony Biosciences Holdings inc   0.62 $ 296.434  Millions$ 481.332  Millions
Scynexis Inc   0.61 $ 56.555  Millions$ 91.991  Millions
Revelation Biosciences Inc   0.61 $ 5.400  Millions$ 8.819  Millions
Nature s Sunshine Products inc   0.61 $ 93.002  Millions$ 152.011  Millions
Dynavax Technologies Corporation  0.61 $ 368.017  Millions$ 604.916  Millions
Gt Biopharma Inc   0.60 $ 6.051  Millions$ 10.005  Millions
Earth Science Tech Inc   0.57 $ 1.108  Millions$ 1.934  Millions
Werewolf Therapeutics Inc   0.57 $ 63.943  Millions$ 112.443  Millions
Elite Pharmaceuticals Inc   0.57 $ 25.625  Millions$ 45.094  Millions
Therapeuticsmd Inc   0.56 $ 15.701  Millions$ 28.052  Millions
Oramed Pharmaceuticals Inc   0.55 $ 81.273  Millions$ 148.230  Millions
Tango Therapeutics Inc   0.55 $ 151.594  Millions$ 276.595  Millions
Hepion Pharmaceuticals inc   0.54 $ 8.732  Millions$ 16.159  Millions
Arcturus Therapeutics Holdings Inc   0.54 $ 150.570  Millions$ 280.062  Millions
Cervomed Inc   0.51 $ 4.927  Millions$ 9.574  Millions
Ardelyx Inc   0.51 $ 98.218  Millions$ 191.161  Millions
Longeveron Inc   0.51 $ 3.394  Millions$ 6.632  Millions
Bicycle Therapeutics Plc  0.51 $ 212.238  Millions$ 416.022  Millions
Hcw Biologics Inc   0.49 $ 11.749  Millions$ 23.867  Millions
Alpine Immune Sciences Inc   0.49 $ 78.916  Millions$ 161.631  Millions

Date modified: 2023-11-14T17:41:48+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com